Elsevier

Maturitas

Volume 65, Issue 4, April 2010, Pages 340-347
Maturitas

Review
New drug treatments for urinary incontinence

https://doi.org/10.1016/j.maturitas.2009.12.022Get rights and content

Abstract

Urinary incontinence remains a common and distressing condition affecting many women and is known to have a significant effect on quality of life (QoL). Whilst conservative and behavioural therapy are important in the management of women with both stress incontinence and overactive bladder (OAB) ultimately many may benefit from pharmacological therapy. Antimuscarinic drugs are the commonly used agents in the treatment of OAB although often compliance and persistence are affected by adverse effects. Consequently many newer agents remain under investigation. In addition duloxetine has recently been introduced for the management of women with stress incontinence and may offer an alternative to surgery in selected cases.

The aim of this review is to provide an overview of the current and new developments in the management of women with urinary incontinence as well as reviewing the role of oestrogen therapy in relation to lower urinary tract dysfunction.

Introduction

Urinary incontinence, the ‘complaint of any involuntary leakage of urine’ [1] is a common and distressing condition known to adversely affect quality of life (QoL) [2] which is often under-reported and under treated.

The prevalence of urinary incontinence has been reported in a large epidemiological study of 27,936 women from Norway [3]. Overall 25% of women reported urinary incontinence of which 7% felt it to be significant and the prevalence was found to increase with age. When considering the type of incontinence, 50% of women complained of stress, 11% urge and 36% mixed incontinence.

Whilst a conservative approach to the management of urinary incontinence is justified in almost all cases drug therapy remains integral in women complaining of overactive bladder (OAB) and has more recently become a treatment option in women with bothersome stress urinary incontinence.

The aim of this paper is to provide a comprehensive overview of the medical management of women with urinary incontinence.

Section snippets

Overactive bladder

Overactive bladder (OAB) is the term used to describe the symptom complex of urgency with, or without urge incontinence, usually with frequency and nocturia [1]. Epidemiological studies have reported the overall prevalence of OAB in women to be 16.9% suggesting that there could be 17.5 million women in the United States of America who suffer from the condition. The prevalence increases with age, being 4.8% in women under 25 years to 30.9% in those over the age of 65 years [4]. This is supported

Oxybutynin

Oxybutynin is a tertiary amine that undergoes extensive first-pass metabolism to an active metabolite, N-desmethyl oxybutynin [8] which occurs in high concentrations [9] and is thought to be responsible for a significant part of the action of the parent drug. It has a mixed action consisting of both an antimuscarinic and a direct muscle relaxant effect in addition to local anaesthetic properties.

The effectiveness of oxybutynin in the management of patients with detrusor overactivity is well

Tolterodine

Tolterodine is a competitive muscarinic receptor antagonist with relative functional selectivity for bladder muscarinic receptors [20] and whilst it shows no specificity for receptor subtypes it does appear to target the bladder over the salivary glands [21]. The drug is metabolised in the liver to the 5-hydroxymethyl derivative which is an active metabolite having a similar pharmacokinetic profile and is thought to significantly contribute to the therapeutic effect [22].

Several randomised,

Imipramine

Imipramine has been shown to have systemic anticholinergic effects [58] and blocks the re-uptake of serotonin. Some authorities have found a significant effect in the treatment of patients with detrusor overactivity [59] although others report little effect [60]. In light of this evidence and the serious adverse effects associated with tricyclic anti-depressants their role in detrusor overactivity remains of uncertain benefit although they are often useful in patients complaining of nocturia or

Desmopressin

Desmopressin (1-desamino-8-d-arginine vasopressin; DDAVP) is a synthetic vasopressin analogue. It has strong anti-diuretic effects without altering blood pressure. The drug has been used primarily in the treatment of nocturia and nocturnal enuresis in children [61] and adults [62]. More recently nasal desmopressin has been reported as a ‘designer drug’ for the treatment of daytime urinary incontinence [63]. Desmopressin is safe for long term use, however the drug should be used with care in the

NICE guidelines

The medical management of OAB has recently been reviewed in the UK by the National Institute for Health and Clinical Excellence (NICE) [64]. In the first instance bladder retraining lasting for a minimum of 6 weeks should be offered to all women with mixed or urge incontinence. In those women who do not achieve satisfactory benefit from bladder retraining alone the combination of an antimuscarinic agent, in addition to bladder retraining should be considered.

When considering drug therapy

Stress urinary incontinence

The term urinary stress incontinence may be used to describe the symptom or sign of urinary leakage on coughing or exertion but should not be regarded as a diagnosis. A diagnosis of urodynamic stress incontinence (USI) may only be made after urodynamic investigation and this is defined as the involuntary leakage of urine during increased abdominal pressure in the absence of a detrusor contraction [1].

Whilst various agents such as α1 adrenoceptor agonists, oestrogens and tricyclic

Duloxetine

Duloxetine is a potent and balanced serotonin (5-hydroxytryptamine) and noradrenaline reuptake inhibitor (SNRI) which enhances urethral striated sphincter activity via a centrally mediated pathway [65]. The efficacy and safety of duloxetine (20 mg, 40 mg, 80 mg) has been evaluated in a double-blind randomised parallel group placebo-controlled phase II dose finding study in 48 centres in the United States involving 553 women with stress incontinence [66]. Duloxetine was associated with significant

Oestrogens in the management of incontinence

Oestrogen preparations have been used for many years in the treatment of urinary incontinence [70], [71] although their precise role remains controversial. Many of the studies performed have been uncontrolled observational series examining the use of a wide range of different preparations, doses and routes of administration. The inconsistent use of progestogens is also a further confounding factor making interpretation of the results difficult.

Systemic oestrogen therapy

The role of systemic oestrogen replacement therapy in the prevention of ischaemic heart disease was assessed in the 4-year randomized Heart and Estrogen/progestin Replacement Study (HERS) [72] involving 2763 postmenopausal women younger than 80 years with intact uteri and ischaemic heart disease. In the study 55% of women reported at least one episode of urinary incontinence each week, and were randomly assigned to oral conjugated oestrogen plus medroxyprogesterone acetate or placebo daily.

Oestrogens in the management of stress urinary incontinence

Oral oestrogens have been reported to increase the maximum urethral pressures and lead to symptomatic improvement in 65–70% of women [76], [77] although other work has not confirmed this [78], [79]. In addition two placebo-controlled studies have been performed examining the use of oral oestrogens in the treatment of urodynamic stress incontinence in postmenopausal women. Neither conjugated equine oestrogens and medroxyprogesterone [80], or unopposed oestradiol valerate [81] showed a

Oestrogens in the management of overactive bladder

Oestrogens have been used in the treatment of urinary urgency and urge incontinence for many years although there have been few controlled trials to confirm their efficacy. A double-blind placebo-controlled crossover study using oral oestriol in 34 postmenopausal women produced subjective improvement in 8 women with mixed incontinence and 12 with urge incontinence [83]. However, a double-blind multicentre study of the use of oestriol (3 mg/d) in postmenopausal women complaining of urgency has

Oestrogen therapy—Cochrane review

The most recent meta-analysis of the effect of oestrogen therapy on the lower urinary tract has been performed by the Cochrane group [90]. Overall 33 trials were identified, including 19 313 incontinent women (1262 involved in trials of local administration) of which 9417 received oestrogen therapy.

Overall systemic administration (of unopposed oral oestrogens) resulted in worse incontinence than on placebo (RR 1.32; 95% CI: 1.17–1.48) although this result is heavily influenced by the weight of

Conclusion

Pharmacological therapy, in addition to bladder retraining remains important in the management of women with symptoms of the overactive bladder and has a more limited role in women with stress urinary incontinence. Whilst tolerability has previously limited compliance the development of long acting agents with an improved adverse event profile has improved this substantially. The development of new M3 specific and bladder selective muscarinic antagonists may also further improve efficacy and

Contributor

Linda Cardozo wrote the manuscript, edited and proof read prior to submission.

Competing interest

Dudley Robinson—Consultancy Fees and Speaker Honoraria: Astellas, Ferring, Pfizer, Uroplasty, Gynaecare, Novo Nordisk, SEP. Research: Astellas, Pfizer, Allergan, Plethora. Linda Cardozo—Consultancy Fees and Speaker Honoraria: Astellas, Pfizer, Rotapharm, Schering-Plough, SEP. Research: Astellas, Pfizer, Allergan, Plethora.

Provenance and peer review

Commissioned and externally peer reviewed.

References (97)

  • R.A. Appell

    Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a poled analysis

    Urology

    (1997)
  • P. Van Kerrebroeck et al.

    Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder

    Urology

    (2001)
  • A.C. Diokno et al.

    Prospective, randomised, double blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial

    Mayo Clin Proc

    (2003)
  • R.R. Dmochowski et al.

    Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo controlled interventional study

    Urology

    (2008)
  • L. Cardozo et al.

    Randomised, double blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder

    J Urol

    (2004)
  • F. Haab et al.

    Long-term open label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome

    Eur Urol

    (2005)
  • C.R. Chapple et al.

    A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial

    Eur Urol

    (2005)
  • L. Cardozo et al.

    Increased warning time with Darifenacin: a new concept in the management of urinary urgency

    J Urol

    (2005)
  • A. Wagg et al.

    Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis

    Am J Geriatr Pharmacother

    (2006)
  • V.A. Alabaster

    Discovery and development of selective M3 antagonists for clinical use

    Life Sci.

    (1997)
  • F. Haab et al.

    Darifenacin an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder

    Eur Urol

    (2004 Apr)
  • C.R. Chapple

    Darifenacin is well tolerated and provides significant improvement in the symptoms of overactive bladder: a pooled analysis of phase III studies

    J Urol

    (2004)
  • C. Chapple et al.

    Fesoterodine in non-neurogenic voiding dysfunction—results on efficacy and safety in a phase III trial

    Eur Urol Suppl

    (2006)
  • P.A. Norton et al.

    Duloxetine versus placebo in the treatment of stress urinary incontinence

    Am J Obstet Gynaecol

    (2002)
  • V.H. Youngblood et al.

    Senile urethritis in women

    J Urol

    (1957)
  • D. Grady et al.

    Postmenopausal hormones and incontinence: the Heart and Estrogen/progestin Replacement Study

    Obstet Gynaecol

    (2001)
  • L.D. Cardozo et al.

    Oestriol in the treatment of postmenopausal urgency: a multicentre study

    Maturitas

    (1993)
  • K. Nilsson et al.

    Low dose oestradiol in the treatment of urogenital oestrogen deficiency—a pharmacokinetic and pharmacodynamic study

    Maturitas

    (1992)
  • P.S. Eriksen et al.

    Low dose 17β-oestradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study

    Eur J Obstet Gynaecol Reprod Biol

    (1992)
  • R.M. Levin et al.

    Experimental hyperreflexia: effect of intravesical administration of various agents

    Pharmacology

    (1991)
  • K.E. Andersson

    The overactive bladder: pharmacologic basis of drug treatment

    Urology

    (1997)
  • C. Chapple et al.

    Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized double-blind placebo controlled study (ZD0947IL/0004)

    Eur Urol

    (2006)
  • S.A. Green et al.

    Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence

    J Urol

    (2006)
  • C.R. Chapple et al.

    Clinical proof of concept study (Blossom) shows novel β3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder

    Eur Urol Suppl

    (2008)
  • P. Abrams et al.

    The standardisation of terminology of lower urinary tract function. Report from the standardisation committee of the International Continence Society

    Neurourol Urodynam

    (2002)
  • C.J. Kelleher et al.

    A new questionnaire to assess the quality of life of urinary incontinent women

    Br J Obstet Gynaecol

    (1997)
  • W.F. Stewart et al.

    Prevalence of overactive bladder in women: results from the NOBLE program

    Int Urogynaecol J

    (2001)
  • I. Milsom et al.

    How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study

    BJU Int

    (2001)
  • D.E. Irwin et al.

    Population-based survey of urinary incontinence, overactive bladder and other lower urinary tract symptoms in five countries; results of the EPIC study

    Eur Urol

    (2006)
  • K.M. Hughes et al.

    Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers

    Xenobiotica

    (1992)
  • L.D. Cardozo et al.

    Oxybutynin chloride in the management of idiopathic detrusor instability

    Neurourol Urodyn

    (1987)
  • R.J. Baigrie et al.

    Oxybutynin: is it safe?

    Br J Urol

    (1988)
  • A. Haruno et al.

    Effects of propiverine hydrochloride and its metabolites on isolated guinea pig urinary bladder

    Folia Pharmacol Jpn

    (1989)
  • D. Mazur et al.

    Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence

    Scand J Urol Nephrol

    (1995)
  • M. Stoher et al.

    Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia: a double-blind, placebo-controlled clinical trial

    Spinal Cord

    (1999)
  • J.W. Thuroff et al.

    Medical treatment and medical side effects in urinary incontinence in the elderly

    World J Urol

    (1998)
  • J.M. Ruscin et al.

    Tolterodine use for symptoms of overactive bladder

    Ann Pharmacother

    (1999)
  • C.J. Hills et al.

    Tolterodine Drugs

    (1998)
  • Cited by (0)

    View full text